Vivos Inc. (RDGL) Fair Value 2026

RDGL · Medical Devices ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

6.4 /10

32 fundamental signals · 1 models active

Value Trap Risk

SAFE (22/100)

Quick Summary — As of 2026-08-27, Vivos Inc. (RDGL) trades at $0.05. QOC: 6.4/10. Value Trap Risk: 22/100 (SAFE). 1/13 models active.

Key Facts

Ticker
RDGL
Price
$0.05
Quality Score
6.4/10
Value Trap Risk
22/100
Models Active
1/13
Last Updated
Strength: 1 independent models provide multi-angle coverage
Risk: Majority of models suggest overvaluation

What Fair Value Does Each Model Give RDGL?

1 Intrinsic Value Models vs. Current Price ($0.05)

Core Models (Unlocked)
Model Fair Value Upside
Asset-Based · High Conviction
 $0.01 -89.1%

All Models Active

All 1 models are displayed above.

What Is Vivos Inc. (RDGL) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, Vivos Inc.'s intrinsic value is estimated at $0.01, suggesting the stock is overvalued at its current price of $0.05. With 1 out of 1 models flagging downside (-89.1% vs price), the market may be pricing in unsustainable growth.

What Do the Models Say About RDGL?

1 of 13 models are currently active for RDGL. All 1 active models suggest the stock trades above fair value. See which stocks rank higher →

How Does RDGL Rank in Medical Devices?

Among 157 Medical Devices stocks, RDGL ranks #74 by Quality of Company score. CirclFi's QOC score of 6.4/10 evaluates 32 fundamental signals. A score of 6.4 indicates above-average quality.

See all Most Undervalued Medical Devices Stocks →

As a pharmaceutical industry, Vivos Inc. operates in a sector where clinical trial success rate is a critical driver of valuation. Investors evaluating RDGL should weigh these sector-specific dynamics alongside our model-derived fair values.

Is RDGL a Value Trap?

CirclFi's Value Trap algorithm assigns RDGL a score of 22/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

1 of 13 models are active for Vivos Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi 32-factor quality framework, Vivos Inc.'s fundamental quality profile registers 6.4/10. This respectable score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.

CirclFi runs 13 independent models for each stock. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every RDGL valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across RDGL's 1 active models, average confidence is 51%. Moderate confidence indicates reasonable fit.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy Vivos Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Medical Devices Stocks Should You Also Analyze?

11 related Medical Devices stocks with 13-model coverage

BFLYButterfly Network, Inc.QOC 6.4ECORelectroCore, Inc.QOC 6.4TNDMTandem Diabetes Care, Inc.QOC 6.5APYXApyx Medical CorporationQOC 6.3RXSTRxSight, Inc.QOC 6.5PETVPetVivo Holdings, Inc.QOC 6.3INBSIntelligent Bio Solutions Inc.QOC 5.4RTGNRetinalGenix Technologies Inc.QOC 3.5SIBNSI-BONE, Inc.QOC 7.5IRMDIRADIMED CORPORATIONQOC 9.8PODDInsulet CorporationQOC 9.6

Read investment analysis: BFLY · ECOR · TNDM · APYX · RXST · PETV · INBS · RTGN · SIBN · IRMD · PODD

Which Other Stocks Have a Similar Quality Score to RDGL?

7 companies across all industries closest to RDGL’s Quality of Company score of 6.4/10.

FNWBFirst Northwest BancorpQOC 6.4PNNTPennantPark Investment CorporationQOC 6.4CARAvis Budget Group, Inc.QOC 6.4SGRYSurgery Partners, Inc.QOC 6.4HOFTHooker Furnishings CorporationQOC 6.4RAREUltragenyx Pharmaceutical Inc.QOC 6.4NVDANVIDIA CorporationQOC 10.0

Read investment analysis: FNWB · PNNT · CAR · SGRY · HOFT · RARE · NVDA

Where Does RDGL Sit in CirclFi's Medical Devices Rankings?

RDGL is ranked against every other Medical Devices stock CirclFi covers in each of these screens.

See all Medical Devices stocks ranked →

What Else Do Investors Ask About Vivos Inc.’s Valuation?

What is Vivos Inc.'s intrinsic value in 2026?

CirclFi does not yet have enough active models to publish a median fair value for Vivos Inc. (RDGL). The Quality of Company score is 6.4/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is RDGL overvalued or undervalued right now?

At $0.05, 0 of 1 active models suggest RDGL may be undervalued, while 1 indicate potential overvaluation. The assessment depends on which methodology best fits Vivos Inc.'s business model in Medical Devices.

What does a Quality of Company score of 6.4 mean for RDGL?

Vivos Inc.'s QOC of 6.4/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on RDGL?

CirclFi analyzes RDGL with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 1 of 13 are active for this stock. Read the full methodology →

Is RDGL a value trap in 2026?

Vivos Inc.'s Value Trap score is 22/100 (SAFE). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “CirclFi assigns Vivos Inc. (RDGL) a Quality of Company score of 6.4/10 across 32 fundamental signals as of 2026-08-27.” Source: circlfi.com/stock/RDGL/ · Methodology
Primary sources for this RDGL valuation
  • Financial statements: Vivos Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001449349) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for RDGL as of ; valuations recomputed .